Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

26 janv. 2012 03h42 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals Announces Financial Calendar for 2012

Company Announcement no. 2/2012 To: NASDAQ OMX Copenhagen...
26 janv. 2012 03h42 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S offentliggør finanskalendar for 2012

Selskabsmeddelelse nr. 2/2012 Til: NASDAQ OMX Copenhagen...
04 janv. 2012 03h00 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals Announces Initiation of STRATO Study of LCP-Tacro™ in Kidney Transplant Recipients Experiencing Tremors

Company Announcement no. 1/2012 To: NASDAQ OMX Copenhagen...
04 janv. 2012 03h00 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S offentliggør initiering af STRATO studie af LCP-Tacro™ i nyretransplanterede patienter, der oplever tremor (rysten)

Selskabsmeddelelse nr. 1/2012 Til: NASDAQ OMX Copenhagen...
22 déc. 2011 23h59 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S and Athena Drug Delivery Solutions Pvt. Ltd. announce partnership to develop, manufacture and commercialize its investigational drug AtorFen™ (Fenofibrate-Atorvastin fixed dose combination)

Company Announcement no. 16/2011 To: NASDAQ OMX Copenhagen...
22 déc. 2011 23h59 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S og Athena Drug Delivery Solutions Pvt. Ltd. offentliggør partnerskab om udvikling, fremstilling og kommercialisering af lægemiddelproduktkandidaten AtorFen™ (Fenofibrat-Atorvastatin fastdosiskombination)

Selskabsmeddelelse nr. 16/2011 Til: NASDAQ OMX Copenhagen...
22 déc. 2011 02h04 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals udlicenserer de amerikanske markedsføringsrettigheder til Fenoglide® (fenofibrat) til Santarus og indgår forlig i patentretssagen mod Impax

Selskabsmeddelelse nr. 15/2011 Til: NASDAQ OMX Copenhagen...
22 déc. 2011 02h04 HE | Source: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals announces licensing of US commercial Fenoglide® (fenofibrate) rights to Santarus and settlement of Impax patent litigation

Company Announcement no. 15/2011 To: NASDAQ OMX Copenhagen...
30 nov. 2011 09h32 HE | Source: Veloxis Pharmaceuticals A/S

Nye vedtægter

Selskabsmeddelelse nr. 14/2011 Til: NASDAQ OMX Copenhagen A/S ...
30 nov. 2011 09h32 HE | Source: Veloxis Pharmaceuticals A/S

Articles of Association

Company Announcement no. 14/2011 To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, November 30, 2011 Articles...

Page précédente